AgomAb Therapeutics N.V. American Depositary Shares AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

AGMB

Rank in Stocks #14697
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company... AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Share Price
$5.92
Last synced: 2026-11-17
Market Cap
$288.52M
Change (1 day)
-0.84%
Change (1 year)
-
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Trade AgomAb Therapeutics N.V. American Depositary Shares (AGMB)

Category

Healthcare
EPS for AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
EPS as of December 2025 TTM: $-0.93
According to AgomAb Therapeutics N.V. American Depositary Shares's latest financial reports, its current EPS (TTM) is $-0.93. At the end of 2025 the company had an EPS of $-1.50, a decrease compared to its 2024 EPS of $-1.31.
EPS history for AgomAb Therapeutics N.V. American Depositary Shares from 2022 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.93 -38.21%
2025 $-1.50 14.55%
2024 $-1.31 282.58%
2023 $-0.34 45.21%
2022 $-0.24 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -1,789.50%
US
$-7.08 663.84%
US
$-5.29 470.72%
AU
$21.56 -2,426.03%
NL
$12.73 -1,473.63%
BE

Questions about AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS)

What is AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS)?

AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) over the last twelve months is $-0.93, as of Dec 2025.

What was AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) in 2025?

In 2025, AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) was $-1.50, compared with $-1.31 in 2024.

How has AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) changed since 2022?

From 2022 to 2025, AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) was highest in 2022 ($-0.24) and lowest in 2025 ($-1.50).

How does AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) compare with similar companies?

AgomAb Therapeutics N.V. American Depositary Shares's earnings per share (EPS) ($-0.93) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.